title: Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.
abstract: Twenty-eight patients with histologically proven metastatic or invasive, unresectable pheochromocytomas, which were shown to concentrate and retain tracer doses of [131I]metaiodobenzylguanidine (131I-MIBG), were treated with therapeutic quantities of this radiopharmaceutical. Between one and six doses ranging from 97 to 301 mCi (cumulative dose 111-916 mCi) were administered. Partial response in tumor size was achieved in 8/28 patients and partial biochemical responses in 12/28 patients. No pharmacological toxicity was observed. Mild radiation sickness (nausea, vomiting, anorexia) occurred in 21/28. Minor degrees of leukopenia and thrombocytopenia were observed in 3/28. There were three cases of hypothyroidism but no significant hepatic, renal, adrenocortical or autonomic nervous dysfunction. We conclude that therapeutic 131I-MIBG can achieve significant therapeutic responses in some cases of malignant pheochromocytoma without pharmacological toxicity and only mild radiotoxicity.
authors.affiliation: Department of Internal Medicine, University of Michigan, Ann Arbor 48109-0028.
authors.forename: B
authors.initials: B
authors.lastname: Shapiro
authors.forename: J C
authors.initials: JC
authors.lastname: Sisson
authors.forename: D M
authors.initials: DM
authors.lastname: Wieland
authors.forename: T J
authors.initials: TJ
authors.lastname: Mangner
authors.forename: S M
authors.initials: SM
authors.lastname: Zempel
authors.forename: E
authors.initials: E
authors.lastname: Mudgett
authors.forename: M D
authors.initials: MD
authors.lastname: Gross
authors.forename: J E
authors.initials: JE
authors.lastname: Carey
authors.forename: K R
authors.initials: KR
authors.lastname: Zasadny
authors.forename: W H
authors.initials: WH
authors.lastname: Beierwaltes
mesh_terms: D019797:3-Iodobenzylguanidine; D000293:Adolescent; D000310:Adrenal Gland Neoplasms / Q000453:epidemiology / Q000628:therapy*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007462:Iodobenzenes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010673:Pheochromocytoma / Q000453:epidemiology / Q000628:therapy*; D012189:Retrospective Studies; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D019797:3-Iodobenzylguanidine